Comprehensive Pancancer Analysis of TUBB6 as a Marker for Prognosis and Immunotherapy Response

Background: TUBB6 is a member of the β-tubulin gene family. However, its prognostic value and involvement in immune response remain unclear to date. Here, we assessed the function of TUBB6 in pancancer. Methods: We utilized The Cancer Genome Atlas database, to explore the expression levels and prognosis of TUBB6 in pancancer. Using the cBioPortal and TCGA databases, we assessed immune, mutation, methylation and drug sensitivity of TUBB6. We further used the GeneMANIA and CancerSEA to explore its molecular function. Subsequently, TUBB6 overexpression was to determine its function on COAD in vitro. Results: The results revealed intriguing patterns of TUBB6 expression in different tumor types. TUBB6 levels positively correlated with pathological stage, N stage, and T stage in many cancers. Patients with TUBB6 overexpression in many cancers had poor prognosis. Moreover, we found that TUBB6 expression was positively correlated with TME constituents and DNA methylation in most tumors. In addition, single-cell analysis and GSEA revealed that TUBB6 participates in EMT, hypoxia, and angiogenesis in many cancers. Furthermore, TUBB6 overexpression significantly inhibited cell proliferation, and cycle. Conclusion: TUBB6 participates in the immune infiltration and the prognosis in multiple cancers. These findings suggest that TUBB6 may be a latent prognostic biomarker and immunotherapy target for tumors.